Acadia Pharmaceuticals (ACAD) Current Assets (2010 - 2026)

Acadia Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• On a quarterly basis, Current Assets rose 25.84% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 25.84% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 13.19% from the prior year.
• Current Assets advanced to $1.1 billion in Q1 2026 per ACAD's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Current Assets topped out at $1.1 billion in Q1 2026 and bottomed at $492.6 million in Q2 2023.
• The 5-year median for Current Assets is $675.3 million (2024), against an average of $730.1 million.
• Across the five-year window, Current Assets dropped 19.55% in 2022 and soared 57.92% in 2024, its largest moves.
• Year by year, Current Assets stood at $507.9 million in 2022, then rose by 21.3% to $616.1 million in 2023, then jumped by 52.29% to $938.3 million in 2024, then advanced by 13.19% to $1.1 billion in 2025, then climbed by 3.19% to $1.1 billion in 2026.
• Per Business Quant, the three latest ACAD Current Assets figures stand at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025).